Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

American Journal of Medicine

Volumn 130, Issue 6, 2017, Pages S30-S39

  Staels, Bart ^a  

^a UNIV LILLE   (France)

Author keywords

Cardiovascular outcomes; Empagliflozin; Mechanisms; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

EMPAGLIFLOZIN; ERYTHROPOIETIN; GLUCAGON; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; HORMONE; SODIUM GLUCOSE COTRANSPORTER 2;

ANTIAPOPTOTIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; DIASTOLIC BLOOD PRESSURE; DIURESIS; DRUG ACTIVITY; DRUG MECHANISM; ENERGY TRANSFER; GLUCOSE METABOLISM; GLUCOTOXICITY; HEART PROTECTION; HEMODYNAMICS; HUMAN; LIPID BLOOD LEVEL; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHY; HYPERGLYCEMIA; METABOLISM;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; GLUCOSIDES; HEMODYNAMICS; HORMONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020040943     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.04.009     Document Type: Article

References (90)

1. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. ® trial. Eur Heart J 37 (2016), 1526–1534.
3. Lüscher, T.F., Paneni, F., Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Med 130:suppl 6 (2017), S18–S29.
4. Inzucchi, S.E., Zinman, B., Wanner, C., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
5. Raz, I., Cahn, A., Heart failure: SGLT2 inhibitors and heart failure—clinical implications. Nat Rev Cardiol 13 (2016), 185–186.
6. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
7. Wanner, C., EMPA-REG OUTCOME: the nephrologist's point of view. Am J Med 130:suppl 6 (2017), S63–S72.
8. Fioretto, P., Zambon, A., Rossato, M., Busetto, L., Vettor, R., SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39:suppl 2 (2016), S165–S171.
9. Škrtić, M., Cherney, D.Z., Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24:1 (2015), 96–103.
10. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003), 1050–1065.
11. Herzog, C.A., Asinger, R.W., Berger, A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:6 (2011), 572–586.
12. Matsushita, K., van der Velde, M., Astor, B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
13. Foley, R.N., Murray, A.M., Li, S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005), 489–495.
14. Wang, Y., Katzmarzyk, P.T., Horswell, R., Zhao, W., Johnson, J., Hu, G., Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int 85 (2014), 1192–1199.
15. Schiffrin, E.L., Lipman, M.L., Mann, J.F., Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (2007), 85–97.
16. Lutz, J., Menke, J., Sollinger, D., Schinzel, H., Thurmel, K., Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29:1 (2014), 29–40.
17. Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 42:2 (2016), 71–76.
18. Abdul-Ghani, M., Del Prato, S., Chilton, R., DeFronzo, R.A., SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 39 (2016), 717–725.
19. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
20. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
21. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
22. DeFronzo, R.A., The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabetes Complications 30:1 (2016), 1–2.
23. Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372 (2015), 2197–2206.
24. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
25. Sattar, N., Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 56:4 (2013), 686–695.
26. Cefalu, W.T., Leiter, L.A., Yoon, K.H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
27. Bolinder, J., Ljunggren, Ö., Johansson, L., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16 (2014), 159–169.
28. Ridderstråle, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
29. Fox, C.S., Pencina, M.J., Wilson, P.W., Paynter, N.P., Vasan, R.S., D'Agostino, R.B. Sr., Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 31 (2008), 1582–1584.
30. Ptaszynska, A., Hardy, E., Johnsson, E., Parikh, S., List, J., Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 125 (2013), 181–189.
31. Schernthaner, G., Gross, J.L., Rosenstock, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36 (2013), 2508–2515.
32. Wilding, J.P., Charpentier, G., Hollander, P., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67 (2013), 1267–1282.
33. Odden, M.C., Amadu, A.R., Smit, E., Lo, L., Peralta, C.A., Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis 64:4 (2014), 550–557.
34. Haas, B., Eckstein, N., Pfeifer, V., Mayer, P., Hass, M.D., Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes, 4, 2014, e143.
35. Campos, C., Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med 124 (2012), 90–97.
36. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107:9 (2010), 1058–1070.
37. Dassanayaka, S., Jones, S.P., O-GlcNAc and the cardiovascular system. Pharmacol Ther 142 (2014), 62–71.
38. Karunakaran, U., Jeoung, N.H., O-GlcNAc modification: friend or foe in diabetic cardiovascular disease. Korean Diabetes J 34 (2010), 211–219.
39. Montaigne, D., Marechal, X., Coisne, A., et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130 (2014), 554–564.
40. Al Jobori, H., Daniele, G., Martinez, R., et al. Empagliflozin improves beta-cell function measured with the hyperglycemic clamp in T2DM. Diabetes, 65, 2016, A286.
41. Kern, M., Kloting, N., Mark, M., Mayoux, E., Klein, T., Bluher, M., The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 65:2 (2016), 114–123.
42. Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
43. Daniele, G., Xiong, J., Solis-Herrera, C., et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39 (2016), 2036–2041.
44. DeFronzo, R.A., Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53 (2010), 1270–1287.
45. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
46. Buse, J.B., DeFronzo, R.A., Rosenstock, J., et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39 (2016), 198–205.
47. El Messaoudi, S., Rongen, G.A., Riksen, N.P., Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep, 15(4), 2013, 314.
48. Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
49. Seferovic, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36 (2015), 1718–1727 1727a-1727c.
50. Lehrke, M., Marx, N., Diabetes mellitus and heart failure. Am J Med 130:suppl 6 (2017), S40–S50.
51. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
52. Fillmore, N., Mori, J., Lopaschuk, G.D., Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171 (2014), 2080–2090.
53. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
54. Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
55. Jorgensen, N.B., Pedersen, J., Vaag, A.A., EMPA-REG: glucose excretion and lipid mobilization - not storage - saves lives. J Diabetes Complications, 30(4), 2016, 753.
56. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
57. Taegtmeyer, H., Failing heart and starving brain: ketone bodies to the rescue. Circulation 134 (2016), 265–266.
58. Lopaschuk, G.D., Verma, S., Empagliflozin's fuel hypothesis: not so soon. Cell Metab 24 (2016), 200–202.
59. Newman, J.C., Verdin, E., Beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract 106:2 (2014), 173–181.
60. Newman, J.C., Verdin, E., Ketone bodies as signaling metabolites. Trends Endocrinol Metab 25 (2014), 42–52.
61. Maalouf, M., Sullivan, P.G., Davis, L., Kim, D.Y., Rho, J.M., Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145 (2007), 256–264.
62. Haces, M.L., Hernandez-Fonseca, K., Medina-Campos, O.N., Montiel, T., Pedraza-Chaverri, J., Massieu, L., Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp Neurol 211:1 (2008), 85–96.
63. McMurray, J., EMPA-REG - the “diuretic hypothesis”. J Diabetes Complications 30 (2016), 3–4.
64. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
65. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37:42 (2016), 3192–3200.
66. Nainggolan, L., How is empagliflozin working in type 2 diabetes in EMPA-REG?. Available at: http://www.medscape.com/viewarticle/865481 Accessed August 12, 2016.
67. Sarafidis, P.A., Tsapas, A., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 374, 2016, 1092.
68. Zinman, B., Lachin, J.M., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. (Correspondence) N Engl J Med, 374, 2016, 1094.
69. Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
70. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
71. Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab 42:4 (2016), 224–233.
72. Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A., Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
73. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
74. Rajasekeran, H., Lytvyn, Y., Cherney, D.Z., Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89 (2016), 524–526.
75. Fischereder, M., Schonermarck, U., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 374 (2016), 1092–1093.
76. Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
77. Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol, 15(1), 2016, 123.
78. Jones, B.J., Tan, T., Bloom, S.R., Minireview: glucagon in stress and energy homeostasis. Endocrinology 153 (2012), 1049–1054.
79. Bonner, C., Kerr-Conte, J., Gmyr, V., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
80. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86 (2014), 1057–1058.
81. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
82. Tikkanen, I., Chilton, R., Johansen, O.E., Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 25:2 (2016), 81–86.
83. Muskiet, M.H., van Raalte, D.H., van Bommel, E.J., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
84. Jiang, F., Yang, J., Zhang, Y., et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11 (2014), 413–426.
85. Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
86. Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
87. Lipšic, E., Westenbrink, B.D., van der Meer, P., et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10 (2008), 22–29.
88. Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
89. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
90. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.